SC 13G/A 1 albany-13ga.txt ALBANY MOLECULAR 13G A =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Albany Molecular Research, Inc. --------------------------------------- (Name of Issuer) COMMON STOCK, $.01 PAR VALUE --------------------------------------------------------------------------- (Title of Class of Securities) 012423 10 9 ----------------- (CUSIP Number) December 31, 2001 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ x ] Rule 13d-1(d) =========================================================================== --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] --------------------------------------------------------------------------- 3) SEC Use Only --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With _________________________________________________ 8) Shared Dispositive Power 0 --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) --------------------------------------------------------------------------- 12) Type of Reporting Person CO --------------------------------------------------------------------------- --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] ] a Member of a Group (b)[ x ] --------------------------------------------------------------------------- 3) SEC Use Only --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of _______________________________________________ Shares Beneficially 6) Shared Voting 0 Owned by _______________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ________________________________________________ 8) Shared Dispositive Power 0 --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) --------------------------------------------------------------------------- 12) Type of Reporting Person CO --------------------------------------------------------------------------- This Amendment No. 1 to Statement on Schedule 13G with respect to the Common Stock of Albany Molecular Research, Inc. (the "Issuer"), is filed solely to amend Item 5(e), to set forth that during the year ended December 31, 2001, Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS -------------------------------------------------------------------------------- (e) API and Pharma each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer during the year ended on December 31, 2001. SIGNATURES ------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: February 8, 2002 By: /s/ Edward H. Stratemeier -------------------------- Edward H. Stratemeier Vice President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: February 8, 2002 By: /s/ Phillip R. Ridolfi ----------------------------------- Phillip R. Ridolfi President